
Opinion|Videos|March 13, 2025
Overall Survival Benefit Update From RATIONALE-305
Panelists discuss how RATIONALE-305 trial data shows promising updated overall survival benefits for patients receiving tislelizumab plus chemotherapy compared to placebo plus chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
2
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
3
Lung Cancer News Roundup: June 2026
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5









































